Phibro Animal Health Corporatio (PAHC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Phibro Animal Health Corporatio

NasdaqGM•Healthcare•Drug Manufacturers - Specialty & Generic

$35.62-0.96(-0.03%)Pre-market

Market Cap

$1.44B

P/E

14.5x

P/S

1.0x

P/B

3.7x

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

How this company scores

GoodMetricSide Score: 70/100

Strongest: Growth (24/25); weakest: Cash & Earnings Quality (8/25).

Profitability23/25

Growth24/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Growing revenueHigh ROERising earningsProfit converts from growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 14.5x5y range 14.5x – 360.9x

Currently below its 20-quarter median.

P/S · 1.0x5y range 0.7x – 1.4x

Currently near its 20-quarter median.

P/B · 3.7x5y range 3.1x – 6.0x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.2x) — earnings may be inflated by non-cash items or aggressive accounting.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $1.44B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $1.52B
Q. Revenue: $396.75M
TTM EBITDA: $245.91M
TTM Op. Income: $194.40M
Q. Op. Income: $48.16M
TTM Net Income: $99.72M
Q. Net Income: $21.71M
EPS: $0.535
Shares Out.: $40.56M

$1.52B in TTM revenue grew 17.1% YoY, reaching $396.75M last quarter. TTM EBITDA of $245.91M and TTM operating income of $194.40M show growth is flowing through to the bottom line. TTM net income of $99.72M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 33.9%
EBITDA Margin: 15.5%
Op. Margin: 12.1%
Net Margin: 5.5%

Op. margin of 12.1% is up 3.2% YoY — cost efficiency is improving. Net margin at 5.5% and gross margin of 33.9% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 36% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 14.5x
P/S Ratio: 1.0x
P/B Ratio: 3.7x

At 14.5x P/E, the stock trades below typical market levels. P/S of 1.0x and P/B of 3.7x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 32% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.50B
Cash: $61.42M
Long-Term Debt: $591.77M
Book Value: $385.48M
D/E Ratio: 1.5
Debt/EBITDA: 9.6

With $1.50B in assets and $591.77M in long-term debt, D/E is 1.5and book value is $385.48M — moderate leverage. Across the last 8 quarters, debt/equity has fallen for 6 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $24.09M
TTM Free Cash Flow: $9.87M
FCF Margin: 0.6%
FCF / Net Income: 0.1

TTM FCF of $9.87M on $24.09M in operating cash flow. The FCF / Net Income ratio of 0.1x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.